Drug intelligence / Profile preview

LSPN904

Development stage: Unknown
Modality: Small Molecules

Overview

LSPN904 appears to be an experimental small-molecule research compound from a coumarin-dihydropyrimidinone hybrid series described in the medicinal chemistry literature. Based on the provided evidence, it is part of an anticancer discovery program evaluating cytotoxic activity in cancer cell lines, but the specific structure, intended molecular target, developer, mechanism of action, and development stage for LSPN904 were not identified. The supplied publication excerpt discusses a related compound, LSPN925, rather than LSPN904 directly, so any more specific annotation for LSPN904 would be speculative.

Beyond the preview

Go deeper on LSPN904.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LSPN904.

Explore the full profile